CMS To Meet With NASPE/HRS, Manufacturers To Review ICD Decision Process
This article was originally published in The Gray Sheet
Executive Summary
Guidant maintains that its MADIT-II trial ethically could not have been extended to provide more evidence of the long-term benefits of ICDs for the entire study population